Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in…

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss Console unit sales increased 88% year-to-date versus pri

Event · Earnings
Original reporting
Published Nov 12, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NUWE
Bullish
high confidence
Mentioned
$NUWE
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NUWEBullishMed
01

Why it matters

The earnings beat on operating loss and margin expansion may trigger short‑term buying, but the small scale tempers the move.

02

Market read

First‑report earnings release for a micro‑cap med‑tech company with improved profitability metrics.

03

What to watch

Cash balance remains low at $8.3 M and the company still relies on future FDA label expansion for growth.

Relevance 7/10Novelty 7/10Timing: pre‑market today ahead of the 9:00 a.m. Eastern conference call
AlphAI · Earnings readNUWE · Q3 2026 · ended 2026-09-30

Nuwellis cuts Q3 operating loss 24% on 430 bp gross margin expansion and 13% lower operating expenses, but Q3 net sales were flat year over year

→Mixed quarter

Gross margin and operating loss improved and nine-month sales grew 13%, but Q3 net sales were unchanged versus a prior-year quarter that included a $0.4 million backorder, console unit sales in Q3 fell to 8 from 12, and Q3 net loss of $(1,969) thousand compared with net income of $468 thousand a year earlier, which included a warrant fair value gain.

Revenue
$2.21M
approximately 12% q/q
Pediatrics
Not disclosed in dollars in the release
20% in Q3 2026; 26% year to date y/y
Gross margin · GAAP
69.5%
430 basis points y/y
EPS · GAAP
$(5.81)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, Q3 2026 (three months ended Sept 30)GAAP$2.21Mapproximately 12%–
Net sales, nine months ended Sept 30, 2026GAAP$6.58M–13%
Cost of goods sold, Q3 2026GAAP$674K––
Cost of goods sold, nine months ended Sept 30, 2026GAAP$1.86M––
Gross profit, Q3 2026GAAP$1.54M––
Gross profit, nine months ended Sept 30, 2026GAAP$4.72M––
Gross margin, Q3 2026GAAP69.5%–430 basis points
Gross margin, nine months ended Sept 30, 2026GAAP71.7%––
Selling, general and administrative expenses, Q3 2026GAAP$3.01M––
Research and development expenses, Q3 2026GAAP$584K––
Total operating expenses, Q3 2026GAAP$3.59M–13% reduction
Total operating expenses, nine months ended Sept 30, 2026GAAP$14.51M––
Loss from operations, Q3 2026GAAP−$2.05M–24% improvement
Loss from operations, nine months ended Sept 30, 2026GAAP−$9.79M––
Net (loss) income, Q3 2026GAAP−$1.97M––
Net loss, nine months ended Sept 30, 2026GAAP−$11.34M––
Basic and diluted (loss) income per share, Q3 2026GAAP$(5.81)––
Basic and diluted loss per share, nine months ended Sept 30, 2026GAAP$(93.13)––
Change in fair value of warrant liabilities, Q3 2026GAAP$94K––
Financing expense, nine months ended Sept 30, 2026GAAP−$6.14M––
Net cash used in operating activities, nine months ended Sept 30, 2026GAAP−$9.27M––
Aquadex consoles sold, Q3 2026other8 consoles––
Aquadex consoles sold, nine months ended Sept 30, 2026other32 consoles–88% increase
Pediatric net sales growth, Q3 2026 versus Q3 2025other20% increase–20%
Pediatric net sales growth, nine months ended Sept 30, 2026 versus prior-year periodother26% increase–26%

Segments

SegmentRevenueq/qy/y
PediatricsThe release describes the pediatric segment as a significant growth driver and says the segment's net sales increased 20% in Q3 2026 and 26% year to date versus the prior-year periods. The release does not print the segment's dollar revenue.Not disclosed in dollars in the release–20% in Q3 2026; 26% year to date

Capital returns

  • The release reports no share repurchases or cash dividends.
  • In July 2026 the company raised $3.4 million in gross proceeds in a direct offering.
  • Concurrently, the company received $3.3 million in gross proceeds from the cash exercise of warrants.
  • During Q3 2026 the company received $1.4 million in net proceeds from common shares sold under its ATM.
  • Nine-month cash flow statement shows proceeds from issuance of common stock and warrants, net of $15,392 thousand and issuance of common stock from ATM, net of $1,358 thousand.
  • Q3 2026 deemed dividend attributable to Series J Convertible Preferred Stock was $2 thousand.

What drove it

  • Company explanation: Q3 2026 gross margin of 69.5% reflected increased average selling prices and benefits from the transition to contract manufacturing.
  • Company explanation: the 13% reduction in operating expenses was primarily attributed to outsourced manufacturing efficiencies and efforts to align expenses with the highest-priority commercial and strategic programs.
  • Company explanation: flat Q3 net sales were primarily due to a $0.4 million backorder fulfilled in Q3 2025.
  • Company explanation: nine-month net sales growth was driven by growth in U.S. circuit and console sales.
  • Company explanation: the Q3 2025 net income of about $0.5 million included a significant noncash gain associated with changes in the fair value of warrant liabilities.
  • Console unit sales for nine months rose 88% to 32 consoles, which the company says expands the installed base for future recurring circuit revenue.
  • Business updates: 510(k) submitted to expand the Aquadex indication to pediatric patients weighing five kilograms and above; co-promotion and distribution agreement with Atrility Medical for AtriAmp; second distribution agreement for the pediatric Zorro-Flow external urine collection system.

Concerns

  • Q3 2026 net sales of $2,212 thousand were unchanged from $2,217 thousand in Q3 2025.
  • Q3 2026 Aquadex console sales were 8 versus 12 in the prior-year quarter.
  • Q3 2026 net loss of $(1,969) thousand compares with net income of $468 thousand in Q3 2025, which the release says included a warrant fair value gain.
  • Nine-month financing expense was $(6,138) thousand and nine-month operating loss was $(9,790) thousand, larger than the prior-year $(8,663) thousand.
  • Nine-month operating cash outflow was $(9,272) thousand versus $(7,780) thousand in the prior-year nine months.
  • Nine-month total operating expenses rose to $14,510 thousand from $12,133 thousand, even as Q3 operating expenses fell.
  • Cash on hand increased largely through equity and warrant financing in 2026, including a $3.4 million direct offering and $3.3 million of warrant exercise proceeds in July 2026.

What to watch

  • FDA decision on the 510(k) submission to expand the Aquadex indication to pediatric patients weighing five kilograms and above.
  • Console unit sales and whether the installed base translates into recurring circuit revenue in coming quarters.
  • Q4 2026 net sales comparison, since the prior-year quarter's backorder effect will no longer be a factor in Q3.
  • Whether gross margin gains and operating expense reductions continue, and the operating cash burn rate against the $8.3 million cash balance.
  • Contribution of the Atrility Medical and Zorro-Flow distribution agreements to revenue.
  • Continued use of equity and warrant financing, including ATM sales, to fund operations.

Balance sheet and cash flow

  • Cash and cash equivalents: $8,290 thousand at Sept 30, 2026 versus $1,085 thousand at Dec 31, 2025. The release describes this as approximately $8.3 million.
  • Total assets: $13,445 thousand at Sept 30, 2026 versus $6,118 thousand at Dec 31, 2025.
  • Total liabilities: $3,589 thousand at Sept 30, 2026 versus $3,488 thousand at Dec 31, 2025.
  • Total stockholders' equity: $9,845 thousand at Sept 30, 2026 versus $2,624 thousand at Dec 31, 2025.
  • Net cash used in investing activities, nine months 2026: $(271) thousand versus $(102) thousand in the prior-year nine months.
  • Net cash provided by financing activities, nine months 2026: $16,750 thousand versus $5,888 thousand in the prior-year nine months.
  • Cash paid for the acquisition of Rendiatech, net of cash acquired, was $(164) thousand in the nine months; deferred consideration from the Rendiatech acquisition totals $113 thousand current and $200 thousand non-current on the balance sheet.
  • Restricted cash at Sept 30, 2026 was $107 thousand; cash and restricted cash at period end were $8,397 thousand.

Analysis

Nuwellis reported third-quarter 2026 net sales of $2,212 thousand, essentially unchanged from $2,217 thousand in the prior-year quarter, which the company attributes to a $0.4 million backorder fulfilled in Q3 2025. Sequentially, the release states net sales increased approximately 12% from Q2 2026, but does not print the Q2 figure. For the nine months, net sales rose 13% to $6,584 thousand from $5,846 thousand, and the release attributes this to growth in U.S. circuit and console sales. Pediatric net sales grew 20% in Q3 and 26% year to date, and the company describes pediatrics as a significant growth driver. The release does not print pediatric dollar revenue.

Margins improved. Q3 gross margin was 69.5% versus 65.2%, a 430 basis point gain the company attributes to higher average selling prices and its contract manufacturing transition. Nine-month gross margin was 71.7% versus 59.4%. Q3 cost of goods sold fell to $674 thousand from $772 thousand and gross profit rose to $1,538 thousand from $1,445 thousand.

Cost discipline is visible in Q3 operating expenses, which fell to $3,591 thousand from $4,142 thousand, a 13% reduction that the company attributes to outsourced manufacturing efficiencies and alignment of spending to priority programs. Loss from operations narrowed 24% to $(2,053) thousand from $(2,697) thousand. On a nine-month basis, however, operating expenses rose to $14,510 thousand from $12,133 thousand and operating loss widened to $(9,790) thousand from $(8,663) thousand, with R&D of $3,254 thousand against $1,828 thousand in the prior-year nine months. The release does not provide a nine-month R&D explanation beyond the Rendiatech acquisition, which appears in the cash flow statement as a $757 thousand non-cash IP R&D charge.

Below the operating line, Q3 net loss was $(1,969) thousand against net income of $468 thousand in Q3 2025. The prior-year figure included a warrant fair value gain of $3,161 thousand, and Q3 2026 warrant fair value change was $94 thousand. Nine-month net loss narrowed to $(11,338) thousand from $(15,099) thousand, helped by lower financing expense of $(6,138) thousand against $(10,553) thousand. Basic and diluted loss per share was $(5.81) in Q3 2026 against $177.16 of income per share in Q3 2025, reflecting a much larger share count of 338,384 thousand weighted shares in Q3 2026 versus 2,646 thousand a year earlier.

Cash and equivalents were $8,290 thousand at Sept 30, 2026, up from $1,085 thousand at Dec 31, 2025, mainly reflecting $16,750 thousand of nine-month financing inflows. Operating cash use widened to $(9,272) thousand from $(7,780) thousand for the nine months. The company issued shares and warrants in July 2026 through a $3.4 million direct offering and received $3.3 million from warrant exercises, and it received $1.4 million net from ATM sales in Q3. The release provides no guidance for future periods, so the outlook rests on the business updates: the Aquadex pediatric 510(k) submission, the Atrility Medical co-promotion agreement, and the Zorro-Flow distribution agreement.

Management, verbatim

Although our third quarter faced a tough comparison against the prior-year period when we fulfilled a significant backorder, the underlying momentum in our business remains strong, as evidenced by the growth in our pediatric segment,

Mike McCormick, President and Chief Executive Officer, Nuwellis

Further, by expanding gross margins and maintaining disciplined cost management, we significantly narrowed our operating loss and cash use during the quarter while continuing to invest in the areas that matter most to our long-term growth.

Mike McCormick, President and Chief Executive Officer, Nuwellis

Not in the filing

stated, not guessed
  • Company financial guidance for future periods (none provided in the release).
  • Consensus estimates or analyst expectations (not in the documents).
  • Share price reaction (not in the documents).
  • Q3 2025 year-over-year percentage change for net sales (release says unchanged, no percentage printed).
  • Prior-quarter (Q2 2026) net sales in dollars (release gives only approximately 12% sequential change).
  • Pediatric segment revenue in dollars for Q3 2026 and nine months 2026.
  • Quarter-over-quarter figures for gross margin, operating expenses, operating loss and net loss.
  • Year-over-year percentage changes for Q3 cost of goods sold, gross profit, SG&A, R&D and net loss.
  • Year-over-year percentage change for nine-month gross margin (only levels printed).
  • Year-over-year percentage change for nine-month operating expenses and operating loss (only levels printed).
  • Prior-period comparisons for Q3 consoles sold as a percentage change.
  • Adjusted or non-GAAP measures (none reported).
  • Operating income, EBITDA or free cash flow reconciliations (not reported).
  • Quarter-end cash balance for June 30, 2026 (not printed).

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

NUWE is a Nasdaq‑listed medical‑technology firm focused on cardiorenal solutions.

Company-level read

Ticker impact

$NUWEBullishHigh confidence
Context

NUWE reported Q3 2026 results with a 24% reduction in operating loss, gross margin expansion and a 13% cut in operating expenses.

Expected impact

likely modest upside as the market prices in the loss improvement and margin expansion

Evidence & confidence

The earnings release shows a clear improvement versus prior year, which can attract short‑term buying pressure.

Market effects

Positive signal for the medical‑technology and renal‑care device sector as cost efficiencies and margin gains are demonstrated.

Limited to U.S. small‑cap biotech/med‑tech investors.

Minimal; primarily a micro‑cap earnings update.

Counterpoint

The modest revenue growth and unchanged top‑line may limit upside; investors could remain cautious.

Key entities

  • Mike McCormick

    President and CEO of NUWE, quoted on the results.

Every NUWE earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$NUWEHighAI 8/10

Nuwellis submits FDA application for pediatric Aquadex expansion

Nuwellis (NASDAQ: NUWE) submitted a 510(k) application to the FDA to expand the use of its Aquadex SmartFlow System to pediatric patients weighing 5 kg and above, currently cleared for 20 kg and above. The submission includes clinical data from the ULTRA-Peds Registry and aims to provide treatment options for fluid overload in smaller children. The company's CEO and a medical director commented on the strategic importance and clinical benefits of the expansion.

$NUWEMed

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 13, 2026 Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin Recent capital raise and warrant exercises extend cash runway through second quarter

$NUWEMed

Nuwellis Slumps on Share Sale

Nuwellis (NASDAQ: NUWE) entered a definitive securities purchase agreement for a registered direct offering of 1,310,890 shares at $2.59 per share, with gross proceeds of about $3.1 million from warrant exercises tied to its June 2026 offering. In a concurrent private placement, investors receive warrants for up to 1,310,890 shares at $2.59, exercisable immediately, expiring in five years. Closing expected around Aug. 3, 2026.

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

$NUWEMed

Nuwellis (NUWE) Stock Rallies 90% After Hours: Here's Why it is Trending Nuwellis Shares Surge 90% After

Nuwellis (NASDAQ:NUWE) shares jumped about 90% to $3.59 after the bell Wednesday after trading down 2.07% to $1.89 in the regular session. The move followed a Tuesday update that it installed its first Aquadex SmartFlow systems at a pediatric hospital in Wisconsin. Nuwellis also reported preliminary Q2 revenue growth of 14% YoY and 6-month growth of 20%, with full results due Aug. 13.